These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 16464205)

  • 1. Economic evaluations relating to diabetes: a descriptive review and their compliance with guidance.
    Oliver A; Pritchard C
    Value Health; 2000; 3 Suppl 1():7-14. PubMed ID: 16464205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
    Carrington M; Stewart S
    Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analyses alongside randomised clinical trials.
    Gray AM
    Clin Trials; 2006; 3(6):538-42. PubMed ID: 17170038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.
    Maetzel A; Tugwell P; Boers M; Guillemin F; Coyle D; Drummond M; Wong JB; Gabriel SE;
    J Rheumatol; 2003 Apr; 30(4):891-6. PubMed ID: 12672224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Economic evaluation of drugs. Effectiveness in diabetes therapy].
    Schöffski O
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S106-9; discussion S124-6. PubMed ID: 18686218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
    Roze S; Valentine WJ; Evers T; Palmer AJ
    Curr Med Res Opin; 2006 Jul; 22(7):1415-24. PubMed ID: 16834840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data collection methods in prospective economic evaluations: how accurate are the results?
    Evans CJ; Crawford B
    Value Health; 2000; 3(4):277-86. PubMed ID: 16464192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of models within economic analysis: focus on type 2 diabetes mellitus.
    Coyle D; Lee KM; O'Brien BJ
    Pharmacoeconomics; 2002; 20 Suppl 1():11-9. PubMed ID: 12036380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New agents in the management of type 2 diabetes: do they provide an opportunity for a shift in the treatment paradigm?
    Valdez CA
    J Manag Care Pharm; 2008 Sep; 14(7):650-4. PubMed ID: 18774875
    [No Abstract]   [Full Text] [Related]  

  • 16. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling for health care and other policy decisions: uses, roles, and validity.
    Johnson FR; Paul JE
    Value Health; 2002; 5(1):62-3; author reply 61-2. PubMed ID: 11873387
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.
    Hughes DA; Bagust A; Haycox A; Walley T
    Health Econ; 2001 Oct; 10(7):601-15. PubMed ID: 11747044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proper preference-based outcome measures in economic evaluations of pharmaceutical interventions.
    Gafni A
    Med Care; 1996 Dec; 34(12 Suppl):DS48-58. PubMed ID: 8969314
    [No Abstract]   [Full Text] [Related]  

  • 20. Modeling economic evaluations of pharmaceuticals: manipulation or valuable tool?
    Khan ZM; Miller DW
    Clin Ther; 1999 May; 21(5):896-908; discussion 895. PubMed ID: 10397383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.